BioNTech SE (BNTX) Chief Executive Officer Ugur Sahin reported direct sales of 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and 17,000 ordinary shares on October 2 at $96.7249 per share. Both sales were made under a Rule 10b5-1 trading plan established by Sahin on June 3, 2026.
A separate indirect holding entry dated October 1 lists 39,218,111 ordinary shares held by Medine GmbH, whose sole shareholder is Sahin. Of those shares, 106,721 were held for an individual under a trust arrangement.
BioNTech SE Chief Executive Officer and 10% owner Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 per share on September 29, 2026, and 32,000 shares at $98.1203 per share on September 30. The sales were effected pursuant to a Rule 10b5-1 trading plan established June 3, 2026. An indirect holding entry dated September 29, 2026 reports 39,218,111 ordinary shares held by Medine GmbH; Sahin may be deemed to beneficially own those shares.
BioNTech SE Chief Executive Officer Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, at $98.6882 per share, and 34,000 ordinary shares on September 28, 2026, at $98.4682 per share. Both sales were effected pursuant to a Rule 10b5-1 trading plan established June 3, 2026. As of September 25, 2026, 39,218,111 ordinary shares were held indirectly through Medine GmbH, including 106,721 held for an individual's benefit under a trust arrangement in which Medine GmbH has voting but not dispositive power.
BioNTech SE Chief Executive Officer Ugur Sahin reported direct sales of 30,000 ordinary shares on September 23, 2026, at $99.4027 per share, and 39,000 shares on September 24 at $98.9913 per share. The sales were made under a Rule 10b5-1 trading plan established June 3, 2026. Separately, 39,218,111 ordinary shares were held indirectly through Medine GmbH as of September 23, 2026; Sahin is its sole shareholder and may be deemed to beneficially own them.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 79,000 Ordinary Shares in open-market or private transactions on September 21–22, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. A form-level holding entry shows 39,218,111 Ordinary Shares held indirectly through Medine GmbH, of which 106,721 shares are held in trust where Medine GmbH has voting but not dispositive power; Sahin may be deemed to beneficially own the shares held by Medine GmbH.
BioNTech SE (BNTX) reports that Chief Executive Officer and ten percent owner Ugur Sahin sold a total of 64,000 Ordinary Shares in open-market or private transactions on September 17–18, 2026, at weighted-average prices of $98.5983 and $96.2243 per share, respectively, under a Rule 10b5-1 trading plan established on June 3, 2026.
Following these transactions, an entity associated with Sahin, Medine GmbH, holds 39,218,111 Ordinary Shares indirectly attributed to him, including 106,721 Ordinary Shares held in trust where Medine GmbH exercises voting power but not dispositive power, and Sahin may be deemed to beneficially own these shares.
BioNTech SE (BNTX) announced that its Supervisory Board has approved the appointment of KPMG AG Wirtschaftsprüfungsgesellschaft as the company’s independent auditor for the financial year ending December 31, 2027, subject to election by shareholders at the upcoming Annual General Meeting.
The decision follows a comprehensive and competitive audit tender process overseen by the Audit Committee, which unanimously recommended KPMG. BioNTech states that, although it is not subject to mandatory auditor rotation requirements, periodically reassessing external audit arrangements through such processes is viewed as consistent with good governance practices.
BioNTech SE (BNTX) Chief Executive Officer and ten percent owner Ugur Sahin reported open-market sales of BioNTech ordinary shares under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. He sold 15,000 ordinary shares on September 16, 2026 at an average price of $96.0893 per share and 34,000 ordinary shares on September 15, 2026 at an average price of $96.4893 per share, for total reported sales of 49,000 shares.
Following these transactions, a reported 39,218,111 ordinary shares are held indirectly through Medine GmbH, of which Sahin is the sole shareholder. The filing notes that 106,721 of these shares are held in trust, where Medine GmbH has voting but not dispositive power, and that Sahin may be deemed to beneficially own the shares held by Medine GmbH.
BioNTech SE (BNTX) reported that Chief Executive Officer and major shareholder Ugur Sahin sold a total of 86,000 ordinary shares in mid-September 2026 under a pre-arranged trading plan. He sold 41,000 shares on September 14, 2026 at an average price of 99.4467 per share and 45,000 shares on September 11, 2026 at an average price of 96.9338 per share.
After these sales, an entity associated with him, Medine GmbH, held 39,218,111 ordinary shares indirectly, including 106,721 shares held in trust where Medine GmbH has voting power but not dispositive power. The sales were effected pursuant to a Rule 10b5-1 trading plan established on June 3, 2026.
BioNTech SE (BNTX) reported updated stage 1 data from the global Phase 3 PRESERVE-003 trial of gotistobart (BNT316/ONC-392) in patients with metastatic squamous non-small cell lung cancer whose disease progressed after prior immunotherapy and chemotherapy. In this randomized comparison versus docetaxel, gotistobart monotherapy showed a statistically significant, clinically meaningful improvement in median overall survival.
Among 87 randomized patients (45 gotistobart; 42 docetaxel) and a median follow-up of 25.4 months as of July 17, 2026, median overall survival was 18.5 months with gotistobart versus 10.0 months with docetaxel (hazard ratio 0.56, nominal p=0.0295). Grade ≥3 treatment-related adverse events occurred in 44.4% of patients on gotistobart and 48.8% on docetaxel, indicating a manageable safety profile. The pivotal stage 2 portion of PRESERVE-003 is ongoing at more than 160 sites globally, and gotistobart holds U.S. Fast Track and Orphan Drug Designations and a Breakthrough Therapy Designation in China for related NSCLC indications.